It is expected that senior AIDS researchers will discuss the impact of this deadly disease in the sub-Saharan countries at the International AIDS Conference in Barcelona on Tuesday. The American pharmaceutical research company VaxGen announced at the conference on Monday that its vaccine to prevent AIDS is likely to be available to the public by 2005. VaxGen states that the widespread distribution of this vaccine depends on the success of trials currently being conducted on individuals in North America, Puerto Rico, the Netherlands, and Thailand. Currently, about 40 million people worldwide are infected with HIV, the virus that leads to AIDS. This figure includes 28.5 million people in Africa and 6.6 million in Asia. Relevant officials have identified these two continents as areas experiencing a rapid increase in HIV infection.
International AIDS Conference Focuses on Disease Issues in Africa - 2002-07-09
The International AIDS Conference in Barcelona will address the severe impact of AIDS in sub-Saharan Africa. VaxGen announced a potential vaccine for AIDS could be available by 2005, depending on trial results. With 40 million people infected globally, including millions in Africa and Asia, the urgency of the issue is highlighted.
👥 Key Players
📰 What Happened
At the International AIDS Conference in Barcelona, VaxGen announced that a vaccine for AIDS could be available by 2005, contingent on trial results. The conference highlighted the urgent need to address the rising HIV infection rates in sub-Saharan Africa and Asia.
- Approximately 40 million people worldwide are infected with HIV.
- 28.5 million of these infections are in Africa, indicating a severe regional crisis.
💡 Why It Matters
📚 Background
HIV/AIDS remains a major global health issue, particularly in sub-Saharan Africa where infection rates are highest. The development of effective vaccines is crucial for controlling the epidemic.
🏷️ Entities Mentioned
Translated from the original and edited for English readers. View original source →
Translation confidence: 85%